Date:- 20 October, 2020

  • Changes in patterns of oncology care with the incorporation of immune response in a study of Stage II colon cancer presented at ASCO Quality Care Symposium, and
  • Evaluation of 763 stage III patients published in the Journal of Clinical Oncology

HalioDx SAS, an immuno-oncology diagnostic company, announced the results of a study led by Dr Afsaneh Barzi, MD, PhD, from City of Hope, a comprehensive cancer center based in Southern California. Dr. Barzi presented the Impact of Immune Assessment with Immunoscore® on Patterns of Care In Stage II Colon Cancer at the ASCO Quality Care Symposium on October 9-10, 2020 ( Presentation is available here). The Company also announced publication of a study which provides additional evidence of Immunoscore® clinical value in stage III colon cancer, by identifying which patients will recur and who is likely to benefit from adjuvant chemotherapy (B. Mlecnik et al. , Journal of Clinical Oncology 2020).

In an abstract presented on October 9, 2020 at the ASCO Quality Care Symposium, incorporation of the Immunoscore® classification data into the risk assessment process resulted in changes to the post-surgical management strategy for stage II colon cancer patients 55% of the time. The study design involved a panel of 25 gastrointestinal oncologists from different cancer centers in the US that evaluated several clinical cases (real-life, de-identified stage II cases submitted for clinical Immunoscore® testing).

As City of Hope and other health care institutions embark on fulfilling the potential of precision oncology, diagnostic tests such as Immunoscore offer an evidence-based way to refine adjuvant chemotherapy prescription for stage II colon cancer patients,commented Afsaneh Barzi, MD, PhD, City of Hope, CA, US. Passionate about improving her patients’ quality of life,Dr. Barzi believes innot just leading-edge treatment but also compassionate patient care.“This is why I am exploring strategies to improve patient outcomes,” she said.

In parallel, the new publication in the Journal of Clinical Oncology published earlier in September, explored the subgroup of stage III patients (n=763) from the large SITC study (F. Pagès et al., Lancet 2018). The population of this cohort fits real-world practice settings as it includes both untreated (mostly elderly) and treated stage III patients receiving heterogeneous treatments (5-FU or FOLFOX or XELOX or FOLFIRI).

This study shows that a high Immunoscore is significantly associated with prolonged survival in stage III colon cancer. Our findings suggest that patients with a high Immunoscore will benefit the most from chemotherapy in terms of recurrence risk.said Bernhard Mlecnik, PhD, Inserm UMRS1138 at Cordeliers Research Center, Paris,France.



Related Files